Loading organizations...
§ Private Profile · 8201 164th Avenue North East Suite 330, Redmond, Washington, 98052, United States
Medical device company develops neuromodulation therapies for pediatric and adult patients with focal drug-resistant epilepsy.
Cadence Neuroscience is a Redmond, Washington-based medical device company that develops neuromodulation therapies for pediatric and adult patients suffering from focal drug-resistant epilepsy. The organization utilizes chronic subthreshold cortical stimulation technology, originally derived from Mayo Clinic research, to modulate EEG biomarkers and reduce or eliminate seizure frequency. To support ongoing pivotal clinical trials and pursue regulatory FDA clearance, the enterprise recently secured $26 million in Series B financing. This specific funding round was led by the Angelini Lumira Biosciences Fund, with additional equity participation from prominent institutional investors including F-Prime Capital, LivaNova USA, and JAZZ Venture Partners. The business is currently expanding its corporate governance with independent board directors like Daniel Moore to guide its transition toward commercialization across broader neurological disorder markets. Cadence Neuroscience was founded in 2017 by Kent Leyde.
Cadence Neuroscience has raised $41.0M across 2 funding rounds.
Cadence Neuroscience has raised $41.0M in total across 2 funding rounds.
Cadence Neuroscience is an early-stage medtech company developing an implantable neuromodulation therapy device to treat drug-resistant epilepsy, particularly in children, by detecting brain signals and delivering targeted electrical stimulation for seizure reduction.[1][2][3][4] Headquartered in Redmond, WA, and founded in 2017, it serves patients with refractory epilepsy who lack effective options beyond medications or invasive surgery, addressing an unmet need for personalized, less invasive treatments that aim to enable seizure-free lives.[2][3][6] The company has raised $15M in Series A (to operationalize, license from Mayo Clinic, and plan studies) and $26M in Series B (for clinical trials), growing to over 30 employees with clinical partnerships, showing strong momentum toward first-in-human trials.[1][2]
Cadence Neuroscience was founded in 2017 by Kent Leyde (CEO) and Doug Sheffield (CSO), both with deep expertise in neuroscience and neuromodulation, starting with a vision to advance therapies for drug-resistant epilepsy.[2][5] The core technology originated from Mayo Clinic, where it was incubated and clinically evaluated for refractory epilepsy management; Cadence secured an exclusive license to refine and commercialize it.[2][4][6] Early traction included $15M Series A funding to build the team and initiate patient studies, followed by a pivotal $26M Series B in 2023 from investors like Angelini Ventures (with board participation), fueling device development, clinical preparations, and team expansion to over 30 amid growing partnerships.[1][2]
Cadence rides the neuromodulation wave in medtech, leveraging AI-driven biomarkers and closed-loop stimulation amid rising demand for precision therapies in neurological disorders affecting millions—epilepsy impacts 3 million in the U.S. alone, with drug-resistant cases driving massive unmet needs and costs.[2][6] Timing aligns with maturing brain-computer interfaces and regulatory progress in responsive neurostimulation (e.g., FDA-approved precedents), amplified by post-pandemic focus on chronic disease tech and pediatric innovation gaps.[1][3][4] Market forces like aging populations, epilepsy prevalence, and investor interest in biotech devices (evidenced by $41M+ funding) favor Cadence, while its Mayo Clinic ties elevate ecosystem standards, influencing collaborative models in epilepsy care and potentially expanding to central pain or other disorders.[1][2][5]
Cadence is poised for clinical milestones, with Series B fueling first trials and potential FDA pathways, scaling toward commercialization amid a medtech funding rebound.[1][2] Trends like AI-enhanced neuromodulation, pediatric neurotech prioritization, and value-based care will propel growth, possibly extending to adjacent indications per patents.[5] Its influence may evolve from epilepsy pioneer to broader neural circuit modulator, amplifying impact as seizure-free outcomes validate the model—ultimately fulfilling the promise of hope for drug-resistant patients where current options fall short.[3][6]
Cadence Neuroscience has raised $41.0M across 2 funding rounds. Most recently, it raised $26.0M Series B in May 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 17, 2023 | $26M Series B | Gerry Brunk | Paolo DI Giorgio, Kevin CHU, JAZZ Venture Partners, Livanova, Mayo Clinic, Spectrum Financial Services | Announced |
| Oct 1, 2019 | $15M Series A | JAZZ Venture Partners | The General Partnership, Sonya Dumanis, Mayo Benefactors Innovation Fund, Mayo Clinic | Announced |
Cadence Neuroscience has raised $41.0M in total across 2 funding rounds.
Cadence Neuroscience's investors include Gerry Brunk, Paolo Di Giorgio, Kevin Chu, JAZZ Venture Partners, LivaNova, Mayo Clinic, Spectrum Financial Services, Jazz Venture Partners, The General Partnership, Sonya Dumanis, Mayo Benefactors Innovation Fund.